Search

Displaying results 4091 - 4100 of 10000 in total
  1. Drug

    CX501

    go.drugbank.com/drugs/DB05174
    Investigational

    Cx501 is used to treat epidermolysis bullosa (EB), a rare genetic condition which can lead to contraction of the joints, fusion of fingers and toes, contraction of the mouth membranes and narrowing of … It is developed by Cellerix and is in phase I of clinical trials.

  2. Drug

    Epoetin delta

    go.drugbank.com/drugs/DB11624
    ApprovedWithdrawn

    Epoetin Delta is an ingredient in the EMA-withdrawn product Dynepo.

  3. Drug

    Pizotifen

    go.drugbank.com/drugs/DB06153
    Approved

    Pizotifen hydrochloride is an active ingredient in Sandomigran, which is used for the prophylactic management of migraines. … Sandomigran is available in a number of countries but is not approved by the FDA nor EMA.

    Categories: Adrenergic alpha-1 Receptor Antagonists, Serotonin Receptor Antagonists
  4. Drug

    Trazodone

    go.drugbank.com/drugs/DB00656
    ApprovedInvestigational

    receptor inhibitor (SNRIs) in the treatment of depression. … Trazodone is triazolopyridine derivative from the serotonin receptor antagonists and reuptake inhibitors (SARIs) class of antidepressants.

    Categories: Adrenergic alpha-1 Receptor Antagonists, Serotonin Receptor Antagonists
  5. Drug

    Glasdegib

    go.drugbank.com/drugs/DB11978
    ApprovedInvestigational

    [L11935] Glasdegib targets cancerous cells by inhibiting the sonic hedgehog receptor smoothened (SMO), a transmembrane protein involved in the Hedgehog (Hh) signaling cascade. … Currently, the current gold standard of AML in older patients is still venetoclax with hypomethylation agents, new clinical combinations of glasdegib are being tested in hope of replacing venetoclax due

    Categories: Smoothened Receptor Antagonists
  6. Drug

    Hyaluronidase (human recombinant)

    go.drugbank.com/drugs/DB06205
    ApprovedInvestigational

    [A4033] Hyaluronidase is an enzyme used to improve the absorption and dispersion of parenterally administered fluids, drugs, and contrast agents. … [L13338] The action of hyaluronidase was first described in 1936, and named in 1939.

  7. Target

    P2X purinoceptor 7

    go.drugbank.com/bio_entities/BE0009814
    TargetHumans

    ATP-gated nonselective transmembrane cation channel that requires high millimolar concentrations of ATP for activation (PubMed:17483156, PubMed:25281740, PubMed:9038151). Upon ATP binding, it rapidly opens to allow the influx of small ca...

    Synonyms: ATP receptor, P2Z receptor
  8. Drug

    Kappadione

    go.drugbank.com/drugs/DB09332
    Approved

    Kappadione is a Vitamin K derivative (chemically, it is menadiol sodium diphosphate), previously approved by FDA prior to 1982 and marketed by Lilly Marketing for this drug has been discontinued and is … It has been found to have carcinogenic potential in mammalian cells as well as cytotoxic properties [L1544].

  9. Drug

    Almonertinib

    go.drugbank.com/drugs/DB16640
    ApprovedInvestigational

    Almonertinib is a third-generation EGFR tyrosine kinase inhibitor targeting EGFR-sensitizing and T790M resistance mutations. … [A231859, A231864, A231869] Unlike other third-generation EGFR TKIs, almonertinib is a pyrimidine-based drug that forms a covalent bond to the binding site of the EGFR tyrosine kinase domain.

    Categories: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
  10. Drug

    Bird pepper

    go.drugbank.com/drugs/DB14262
    Approved

    Bird pepper is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.